The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Immunotherapy for Non-Small Cell Lung Cancer using DNA Sequencing?

surf2kona
surf2kona CSN Member Posts: 1 Member

My mother-in-law who is 84 years old was diagnosese with Stage 4a non-small cell lung cancer. Its in the right lung and in some lymph nodes they tested. Nothing in the bones or brain scans. we are still waiting on DNA sequencing.

Does anyone know of a good sources for papers or information about immunotherapy treatments that work for specific DNA types?

Comments

  • eDivebuddy
    eDivebuddy CSN Member Posts: 171 Member

    Sorry your family is going through this. Right now, there aren't any immunotherapy treatments that are reliably tailored to specific DNA mutations in NSCLC. Most targeted therapies are designed for driver mutations like EGFR or ALK, which actually tend to steer people away from immunotherapy. PD-L1 expression and tumor mutational burden (TMB) are still the main biomarkers guiding immunotherapy decisions. Once the sequencing results are in, we can better interpret what they might mean for treatment options but there’s no one-size-fits-all immunotherapy by mutation type yet. KRAS G12C does show some added responsiveness to immunotherapy, but most mutations still respond better to targeted therapy or chemotherapy when applicable.